Dr. Mittendorf Discusses Immunotherapy Efforts in Breast Cancer

Elizabeth A. Mittendorf, MD, PhD
Published: Tuesday, Mar 27, 2018



Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

Mittendorf says that there is some interesting neoantigen work being done at Dana-Farber Cancer Institute, specifically antigen discovery. The goal of antigen discovery is to identify targets for vaccination.

Another area of interest is evaluating the impact of current standard therapies for breast cancer on the immune microenvironment. This is work that Mittendorf plans to continue with the help of collaborators and new technology. Research will focus on both lymphoid and myeloid cells, Mittendorf says.


Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

Mittendorf says that there is some interesting neoantigen work being done at Dana-Farber Cancer Institute, specifically antigen discovery. The goal of antigen discovery is to identify targets for vaccination.

Another area of interest is evaluating the impact of current standard therapies for breast cancer on the immune microenvironment. This is work that Mittendorf plans to continue with the help of collaborators and new technology. Research will focus on both lymphoid and myeloid cells, Mittendorf says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x